Top

Archives of Osteoporosis

Published in:

Open Access 01-12-2018 | Original Article

Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates

Authors: T. Petranova, M. Boyanov, A. Shinkov, R. Petkova, M. Intorcia, E. Psachoulia

Published in: Archives of Osteoporosis | Issue 1/2018

Abstract

Summary

Persistence with osteoporosis therapy is critical for fracture risk reduction. This observational study evaluated medication-taking behaviour of women with postmenopausal osteoporosis receiving denosumab or oral ibandronate in real-world clinical practice in Bulgaria. Compared with ibandronate, densoumab was associated with a lower discontinuation rate and greater increases in bone mineral density.

Purpose

Persistence with osteoporosis therapy is critical for fracture risk reduction and the effectiveness of such treatments may be reduced by low persistence. Alternative therapies such as denosumab may improve persistence. This study aimed to describe medication-taking behaviour in women with osteoporosis, prescribed denosumab or oral ibandronate, in Bulgarian clinical practice.

Methods

This retrospective, observational, multicentre chart review (with up to 24 months follow-up) enrolled postmenopausal women initiating 6-monthly denosumab injection or monthly oral ibandronate treatment for osteoporosis between 1 October 2011 and 30 September 2012.

Results

Overall, 441 women were enrolled (224 had initiated denosumab, 217 had initiated ibandronate). At baseline, more women in the denosumab group than in the ibandronate group had a previous fracture (25.5 vs 17.5%; p = 0.043) and past exposure to osteoporosis therapy (19.6 vs 12.0%; p = 0.028). At 24 months, 4.5% of women receiving denosumab had discontinued therapy compared with 56.2% of women receiving ibandronate. Median time to discontinuation was longer in the denosumab group (729 days; interquartile range (IQR), 728.3–729.0) than in the ibandronate group (367 days; IQR, 354.0–484.8; p < 0.001). At 24 months, there were significantly greater changes in BMD T-scores at the lumbar spine (p < 0.001) and femoral neck (p < 0.001) in patients receiving denosumab than in those receiving ibandronate. At 24 months, persistence with denosumab was 98.7%.

Conclusion

This real-world study demonstrates there is a low discontinuation rate and high persistence with denosumab. Denosumab was associated with greater BMD increases than ibandronate, which could reduce fracture risk.

Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA, EURPo IOF (2013) Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 8(1-2):137. https://doi.org/10.1007/s11657-013-0137-0 CrossRefPubMedPubMedCentral

National Institute of Health (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795CrossRef

Borissova AM, Rashkov R, Boyanov M, Shinkov A, Popivanov P, Temelkova N, Vlahov J, Gavrailova M (2011) Femoral neck bone mineral density and 10-year absolute fracture risk in a national representative sample of Bulgarian women aged 50 years and older. Arch Osteoporos 6(1-2):189–195. https://doi.org/10.1007/s11657-011-0064-x CrossRefPubMed

Borissova A-M, Zacharieva S, Boyanov M, Kovacheva R, Rashkov R, Kolarov Z, Shinkov A (2013) Ministry of Health: recommendations for good clinical practice in osteoporosis. http://www.iofbonehealth.org/sites/default/files/PDFs/National%20Guidelines/Guideline_Osteoporosis_Bulgaria_2013_abstract.pdf. Accessed 19 Oct 2017

Penning-van Beest FJ, Erkens JA, Olson M, Herings RM (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19(4):511–517. https://doi.org/10.1007/s00198-007-0466-1 CrossRefPubMed

Curtis JR, Cai Q, Wade SW, Stolshek BS, Adams JL, Balasubramanian A, Viswanathan HN, Kallich JD (2013) Osteoporosis medication adherence: physician perceptions vs. patients’ utilization. Bone 55(1):1–6. https://doi.org/10.1016/j.bone.2013.03.003 CrossRefPubMedPubMedCentral

Vieira HP, Leite IA, Araujo Sampaio TM, Dos Anjos de Paula J, do Nascimento Andrade A, de Abreu LC, Valenti VE, Goulart FC, Adami F (2013) Bisphosphonates adherence for treatment of osteoporosis. Int Arch Med 6(1):24. https://doi.org/10.1186/1755-7682-6-24 CrossRefPubMedPubMedCentral

Patrick AR, Brookhart MA, Losina E, Schousboe JT, Cadarette SM, Mogun H, Solomon DH (2010) The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab 95(7):3251–3259. https://doi.org/10.1210/jc.2009-2778 CrossRefPubMedPubMedCentral

Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82(12):1493–1501. https://doi.org/10.1016/S0025-6196(11)61093-8 CrossRefPubMed

10.

Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38(6):922–928. https://doi.org/10.1016/j.bone.2005.10.022 CrossRefPubMed

11.

Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81(8):1013–1022. https://doi.org/10.4065/81.8.1013 CrossRefPubMed

12.

Sunyecz JA, Mucha L, Baser O, Barr CE, Amonkar MM (2008) Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int 19(10):1421–1429. https://doi.org/10.1007/s00198-008-0586-2 CrossRefPubMed

13.

Amgen (2014) Prolia® Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001120/WC500093526.pdf. Accessed 19 Oct 2017

14.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. https://doi.org/10.1056/NEJMoa0809493 CrossRefPubMed

15.

Hadji P, Papaioannou N, Gielen E, Feudjo Tepie M, Zhang E, Frieling I, Geusens P, Makras P, Resch H, Moller G et al (2015) Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int 26(10):2479–2489. https://doi.org/10.1007/s00198-015-3164-4 CrossRefPubMedPubMedCentral

16.

Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Strom O (2015) Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int 26(10):2401–2411. https://doi.org/10.1007/s00198-015-3253-4 CrossRefPubMedPubMedCentral

17.

Lakatos P, Takacs I, Marton I, Toth E, Zoltan C, Lang Z, Psachoulia E, Intorcia M (2016) A retrospective longitudinal database study of persistence and compliance with treatment of osteoporosis in Hungary. Calcif Tissue Int 98(3):215–225. https://doi.org/10.1007/s00223-015-0082-6 CrossRefPubMed

18.

Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I, Balasubramanian A, Dakin P, Ho P, Siddhanti S, Stolshek B, Recknor C (2015) Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int 26(1):361–372. https://doi.org/10.1007/s00198-014-2871-6 CrossRefPubMed

19.

Fahrleitner-Pammer A, Papaioannou N, Gielen E, Feudjo Tepie M, Toffis C, Frieling I, Geusens P, Makras P, Boschitsch E, Callens J, Anastasilakis AD, Niedhart C, Resch H, Kalouche-Khalil L, Hadji P (2017) Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium. Arch Osteoporos 12(1):58. https://doi.org/10.1007/s11657-017-0351-2 CrossRefPubMedPubMedCentral

20.

Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL, Investigators D (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23(1):317–326. https://doi.org/10.1007/s00198-011-1780-1 CrossRefPubMed

21.

Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86(3):202–210. https://doi.org/10.1007/s00223-009-9329-4 CrossRefPubMed

22.

Weycker D, Lamerato L, Schooley S, Macarios D, Siu Woodworth T, Yurgin N, Oster G (2013) Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice. Osteoporos Int 24(4):1483–1489. https://doi.org/10.1007/s00198-012-2108-5 CrossRefPubMed

23.

Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15(12):1003–1008. https://doi.org/10.1007/s00198-004-1652-z CrossRefPubMed

24.

Boyanov M, Shinkov A, Psachoulia E, Intorcia M, Petkova R (2017) Baseline characteristics and changes in bone mineral density T-scores of Bulgarian women with postmenopausal osteoporosis receiving denosumab in routine clinical practice. Drugs R D 17(1):125–132. https://doi.org/10.1007/s40268-016-0159-3 CrossRefPubMed

25.

Kendler DL, McClung MR, Freemantle N, Lillestol M, Moffett AH, Borenstein J, Satram-Hoang S, Yang YC, Kaur P, Macarios D et al (2011) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 22(6):1725–1735. https://doi.org/10.1007/s00198-010-1378-z CrossRefPubMed

26.

Yun H, Curtis JR, Guo L, Kilgore M, Muntner P, Saag K, Matthews R, Morrisey M, Wright NC, Becker DJ, Delzell E (2014) Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries. BMC Musculoskelet Disord 15(1):112. https://doi.org/10.1186/1471-2474-15-112 CrossRefPubMedPubMedCentral

27.

Fuksa L, Vytrisalova M (2015) Adherence to denosumab in the treatment of osteoporosis and its utilization in the Czech Republic. Curr Med Res Opin 31(9):1645–1653. https://doi.org/10.1185/03007995.2015.1065241 CrossRefPubMed

28.

Hiligsmann M, Salas M, Hughes DA, Manias E, Gwadry-Sridhar FH, Linck P, Cowell W (2013) Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int 24(12):2907–2918. https://doi.org/10.1007/s00198-013-2364-z CrossRefPubMed

29.

Cooper A, Drake J, Brankin E (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60(8):896–905. https://doi.org/10.1111/j.1742-1241.2006.01059.x CrossRefPubMedPubMedCentral

30.

Kishimoto H, Maehara M (2015) Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Arch Osteoporos 10:231CrossRefPubMed

31.

Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E (2011) The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm 17(1):25–39. https://doi.org/10.18553/jmcp.2011.17.1.25 CrossRefPubMed

32.

Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14(4):571–581. https://doi.org/10.1016/j.jval.2010.11.010 CrossRefPubMed

33.

Petranova T, Sheytanov I, Monov S, Nestorova R, Rashkov R (2014) Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment. Biotechnol Biotechnol Equip 28(6):1127–1137. https://doi.org/10.1080/13102818.2014.967827 CrossRefPubMedPubMedCentral

34.

Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwinski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513–523. https://doi.org/10.1016/S2213-8587(17)30138-9 CrossRefPubMed

35.

McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, Ding B, Rockabrand E, Wagman RB, Miller PD (2013) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 24(1):227–235. https://doi.org/10.1007/s00198-012-2052-4 CrossRefPubMed

36.

Miller PD, Recker RR, Reginster JY, Riis BJ, Czerwinski E, Masanauskaite D, Kenwright A, Lorenc R, Stakkestad JA, Lakatos P (2012) Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. Osteoporos Int 23(6):1747–1756. https://doi.org/10.1007/s00198-011-1773-0 CrossRefPubMed

37.

Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C (2014) Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporos Int 25(7):1953–1961. https://doi.org/10.1007/s00198-014-2692-7 CrossRefPubMed

38.

Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24(1):153–161. https://doi.org/10.1359/jbmr.0809010 CrossRefPubMed

39.

Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster JY, Singer A, Wang C, Wagman RB, Cummings SR (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101(8):3163–3170. https://doi.org/10.1210/jc.2016-1801 CrossRefPubMedPubMedCentral

40.

Ringe JD, Farahmand P (2014) Improved real-life adherence of 6-monthly denosumab injections due to positive feedback based on rapid 6-month BMD increase and good safety profile. Rheumatol Int 34(5):727–732. https://doi.org/10.1007/s00296-012-2663-2 CrossRefPubMed

41.

Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23(1):223–231. https://doi.org/10.1007/s00198-011-1535-z CrossRefPubMed

42.

Landfeldt E, Strom O, Robbins S, Borgstrom F (2012) Adherence to treatment of primary osteoporosis and its association to fractures—the Swedish Adherence Register Analysis (SARA). Osteoporos Int 23(2):433–443. https://doi.org/10.1007/s00198-011-1549-6 CrossRefPubMed

Title: Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates
Authors: T. Petranova
M. Boyanov
A. Shinkov
R. Petkova
M. Intorcia
E. Psachoulia
Publication date: 01-12-2018
Publisher: Springer London
Published in: Archives of Osteoporosis / Issue 1/2018
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI: https://doi.org/10.1007/s11657-017-0413-5

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates

Abstract

Summary

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Summary

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Severe hypoglycemia is associated with high risk for falls in adults with type 1 diabetes

Decreasing trend of hip fractures incidence in Italy between 2007 and 2014: epidemiological changes due to population aging

25-Hydroxyvitamin D levels and bone mineral density evaluation in patients with cholecystectomy: a case-control study

Mild cognitive impairment is associated with poor physical function but not bone structure or density in late adulthood: findings from the Hertfordshire cohort study

The burden and undertreatment of fragility fractures among senior women

Effect of vertebral exclusion on TBS and FRAX calculations